Francesca Palandri, Daniela Bartoletti, Alessandra Iurlo, Massimiliano Bonifacio, Elisabetta Abruzzese, Giovanni Caocci, Elena M Elli, Giuseppe Auteri, Mario Tiribelli, Nicola Polverelli, Maurizio Miglino, Florian H Heidel, Alessia Tieghi, Giulia Benevolo, Eloise Beggiato, Carmen Fava, Francesco Cavazzini, Novella Pugliese, Gianni Binotto, Costanza Bosi, Bruno Martino, Monica Crugnola, Emanuela Ottaviani, Giorgia Micucci, Malgorzata M Trawinska, Antonio Cuneo, Monica Bocchia, Mauro Krampera, Fabrizio Pane, Roberto M Lemoli, Daniela Cilloni, Nicola Vianelli, Michele Cavo, Giuseppe A Palumbo, Massimo Breccia
BACKGROUND: The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB ≥4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF-related splenomegaly and symptoms. Its role has not been assessed in correlation with PB. METHODS: In 794 chronic-phase MF patients treated with RUX, we evaluated the impact of baseline percentage of PB on response (spleen and symptoms responses) and outcome (RUX discontinuation-free, leukemia-free, and overall survival)...
April 1, 2022: Cancer